One-week external beam partial breast irradiation: survival and toxicity outcomes.
Breast cancer
Feasibility
Partial breast irradiation
Radiation therapy
Journal
Journal of cancer research and clinical oncology
ISSN: 1432-1335
Titre abrégé: J Cancer Res Clin Oncol
Pays: Germany
ID NLM: 7902060
Informations de publication
Date de publication:
Sep 2023
Sep 2023
Historique:
received:
04
05
2023
accepted:
04
06
2023
medline:
16
8
2023
pubmed:
17
6
2023
entrez:
17
6
2023
Statut:
ppublish
Résumé
According to ASTRO and ESTRO guidelines, external beam Partial Breast Irradiation (PBI) is a valid option for early-stage breast cancer patients. Nevertheless, there is lack of consensus about the best treatment schedule. We retrospectively analysed data of female patients treated at our institution from 2013 to 2022 with adjuvant "one-week" partial breast irradiation. Clinical Target Volume (CTV) was an isotropic expansion of 15 mm from the tumour bed (identified as the breast tissue between surgical clips). The treatment schedule was 30 Gy delivered with Volumetric Modulated Arc Therapy in 5 daily fractions. The primary endpoint was Local Control (LC). Disease-Free Survival (DFS), Overall Survival (OS) and safety were secondary endpoints. Three hundred and forty-four patients with a median age of 69 (33-87) years were included in the study. After a median follow-up of 34 (7-105) months, 7 patients (2.0%) developed a local recurrence. Three-year LC, DFS and OS actuarial rates were 97.5% (95% CI 96.2%-98.8%), 95.7% (95% CI 94.2%-97.2%), and 96.9% (95% CI 95.7%-98.1%), respectively. Ten (2.9%) patients experienced grade 2 late toxicities. Five (1.5%) patients reported late cardiac major events. Three (0.9%) late pulmonary toxicities were detected. One hundred and five (30.5%) patients reported fat necrosis. Good or excellent cosmetic evaluation following the Harvard Scale was reported in 252 (96.9%) cases by the physicians, while in 241 (89.2%) cases by the patients. "One-week" PBI is effective and safe, and this schedule is a valid option for highly selected early breast cancer patients.
Identifiants
pubmed: 37329461
doi: 10.1007/s00432-023-04973-y
pii: 10.1007/s00432-023-04973-y
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
10965-10974Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Belkacemi Y, Hanna NE, Besnard C, Majdoul S, Gligorov J (2018) Local and regional breast cancer recurrences: salvage therapy options in the new era of molecular subtypes. Front Oncol 17(8):112. https://doi.org/10.3389/fonc.2018.00112
doi: 10.3389/fonc.2018.00112
Bourgier C, Pichenot C, Verstraet R, El Nemr M, Heymann S, Biron B, Delaloge S, Mathieu MC, Garbay JR, Bourhis J, Taghian AG, Marsiglia H (2011) Early side effects of three-dimensional conformal external beam accelerated partial breast irradiation to a total dose of 40 Gy in one week (a phase II trial). Int J Radiat Oncol Biol Phys 81(5):1228–1235. https://doi.org/10.1016/j.ijrobp.2010.07.040
doi: 10.1016/j.ijrobp.2010.07.040
pubmed: 20932662
Buchholz TA, Ali S, Hunt KK (2020) Multidisciplinary management of locoregional recurrent breast cancer. J Clin Oncol 38(20):2321–2328. https://doi.org/10.1200/JCO.19.02806
doi: 10.1200/JCO.19.02806
pubmed: 32442059
pmcid: 8462537
Ciabattoni A, Gregucci F, De Rose F et al (2022) AIRO breast cancer group best clinical practice 2022 update. Tumori J 108(2_suppl):1–144. https://doi.org/10.1177/03008916221088885
doi: 10.1177/03008916221088885
Coles CE, Griffin CL, Kirby AM, Titley J, Agrawal RK, Alhasso A, Bhattacharya IS, Brunt AM et al (2017) Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial. Lancet 390(10099):1048–1060. https://doi.org/10.1016/S0140-6736(17)31145-5
doi: 10.1016/S0140-6736(17)31145-5
pubmed: 28779963
pmcid: 5594247
Correa C, Harris EE, Leonardi MC, Smith BD, Taghian AG, Thompson AM, White J, Harris JR (2017) Accelerated partial breast irradiation: executive summary for the update of an ASTRO evidence-based consensus statement. Pract Radiat Oncol 7(2):73–79. https://doi.org/10.1016/j.prro.2016.09.007
doi: 10.1016/j.prro.2016.09.007
pubmed: 27866865
Cox JD, Stetz J, Pajak TF (1995) Toxicity criteria of the radiation therapy oncology group (RTOG) and the European organization for research and treatment of cancer (EORTC). Int J Radiat Oncol Biol Phys 31(5):1341–1346. https://doi.org/10.1016/0360-3016(95)00060-C
doi: 10.1016/0360-3016(95)00060-C
pubmed: 7713792
Fisher B, Anderson S, Bryant J, Margolese RG, Deutsch M, Fisher ER, Jeong JH, Wolmark N (2002) Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 347(16):1233–1241. https://doi.org/10.1056/NEJMoa022152
doi: 10.1056/NEJMoa022152
pubmed: 12393820
Genova R, Garza RF (2022) Breast fat necrosis. [Updated 2022 Aug 8]. In: StatPearls [internet]. StatPearls Publishing, Treasure Island
Genova R, Garza RF (2023) Breast fat necrosis. [updated 2022 Aug 8]. In: StatPearls [internet]. StatPearls Publishing, Treasure Island. https://www.ncbi.nlm.nih.gov/books/NBK542191/ .
Glynn D, Bliss J, Brunt AM, Coles CE, Wheatley D, Haviland JS, Kirby AM, Longo F, Faria R, Yarnold JR, Griffin S (2022) Cost-effectiveness of 5 fraction and partial breast radiotherapy for early breast cancer in the UK: model-based multi-trial analysis. Breast Cancer Res Treat 17:1–12. https://doi.org/10.1007/s10549-022-06802-1
doi: 10.1007/s10549-022-06802-1
Halsted WS (1894) I. The results of operations for the cure of cancer of the breast performed at the Johns Hopkins hospital from June, 1889, to January, 1894. Ann Surg 20(5):497–555. https://doi.org/10.1097/00000658-189407000-00075
doi: 10.1097/00000658-189407000-00075
pubmed: 17860107
pmcid: 1493925
Harris JR, Levene MB, Svensson G, Hellman S (1979) Analysis of cosmetic results following primary radiation therapy for stages I and II carcinoma of the breast. Int J Radiat Oncol Biol Phys 5(2):257–261. https://doi.org/10.1016/0360-3016(79)90729-6
doi: 10.1016/0360-3016(79)90729-6
pubmed: 110740
Haviland JS, Owen JR, Dewar JA, Agrawal RK, Barrett J, Barrett-Lee PJ, Dobbs HJ et al (2013) The UK standardisation of breast radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. Lancet Oncol 14(11):1086–1094. https://doi.org/10.1016/S1470-2045(13)70386-3
doi: 10.1016/S1470-2045(13)70386-3
pubmed: 24055415
Heins MJ, de Ligt KM, Verloop J, Siesling S, Korevaar JC, PSCCR group (2022) Adverse health effects after breast cancer up to 14 years after diagnosis. Breast 61:22–28. https://doi.org/10.1016/j.breast.2021.12.001
doi: 10.1016/j.breast.2021.12.001
pubmed: 34891036
La Rocca E, Lozza L, D’Ippolito E, Dispinzieri M, Giandini C, Bonfantini F, Valdagni R, Folli S, Pignoli E, Di Cosimo S, De Santis MC (2020) VMAT partial-breast irradiation: acute toxicity of hypofractionated schedules of 30 Gy in five daily fractions. Clin Transl Oncol. 22(10):1802–1808. https://doi.org/10.1007/s12094-020-02319-5
doi: 10.1007/s12094-020-02319-5
pubmed: 32128672
Lazzari G, Terlizzi A, Leo MG, Silvano G (2018) Tumor grade and molecular subtypes on local control in breast cancer radiotherapy: does fractionation really matter? A retrospective control study group. Clin Transl Radiat Oncol 15:7–12. https://doi.org/10.1016/j.ctro.2018.11.008
doi: 10.1016/j.ctro.2018.11.008
pubmed: 30582015
pmcid: 6288309
Livi L, Meattini I, Marrazzo L, Simontacchi G, Pallotta S, Saieva C, Paiar F, Scotti V, De Luca CC et al (2015) Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5-year survival analysis of a phase 3 randomised controlled trial. Eur J Cancer 51(4):451–463. https://doi.org/10.1016/j.ejca.2014.12.013
doi: 10.1016/j.ejca.2014.12.013
pubmed: 25605582
Lövey K, Fodor J, Major T, Szabó E, Orosz Z, Sulyok Z, Jánváry L, Fröhlich G, Kásler M, Polgár C (2007) Fat necrosis after partial-breast irradiation with brachytherapy or electron irradiation versus standard whole-breast radiotherapy–4-year results of a randomized trial. Int J Radiat Oncol Biol Phys 69(3):724–731. https://doi.org/10.1016/j.ijrobp.2007.03.055
doi: 10.1016/j.ijrobp.2007.03.055
pubmed: 17524571
Lozza L, Fariselli L, Sandri M et al (2018) Partial breast irradiation with CyberKnife after breast conserving surgery: a pilot study in early breast cancer. Radiat Oncol 13:49. https://doi.org/10.1186/s13014-018-0991-4
doi: 10.1186/s13014-018-0991-4
pubmed: 29566762
pmcid: 5865347
Marrazzo L, Meattini I, Simontacchi G, Livi L, Pallotta S (2023) Updates on the APBI-IMRT-Florence trial (NCT02104895) technique: from the intensity modulated radiation therapy trial to the volumetric modulated arc therapy clinical practice. Pract Radiat Oncol 13(1):e28–e34. https://doi.org/10.1016/j.prro.2022.05.010
doi: 10.1016/j.prro.2022.05.010
pubmed: 35659597
Meattini I, Marrazzo L, Saieva C, Desideri I, Scotti V, Simontacchi G, Bonomo P, Greto D et al (2020) Accelerated partial-breast irradiation compared with whole-breast irradiation for early breast cancer: long-term results of the randomized phase III APBI-IMRT-Florence trial. J Clin Oncol 38(35):4175–4183. https://doi.org/10.1200/JCO.20.00650
doi: 10.1200/JCO.20.00650
pubmed: 32840419
Meattini I, Becherini C, Boersma L, Kaidar-Person O, Marta GN, Montero A, Offersen BV, Aznar MC, Belka C et al (2022) European society for radiotherapy and oncology advisory committee in radiation oncology practice consensus recommendations on patient selection and dose and fractionation for external beam radiotherapy in early breast cancer. Lancet Oncol 23(1):e21–e31. https://doi.org/10.1016/S1470-2045(21)00539-8
doi: 10.1016/S1470-2045(21)00539-8
pubmed: 34973228
Murray Brunt A, Haviland JS, Wheatley DA, Sydenham MA, Alhasso A, Bloomfield DJ et al (2020) Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial. Lancet 395(10237):1613–1626. https://doi.org/10.1016/S0140-6736(20)30932-6
doi: 10.1016/S0140-6736(20)30932-6
pubmed: 32580883
pmcid: 7262592
Orecchia R, Veronesi U, Maisonneuve P, Galimberti VE, Lazzari R, Veronesi P, Jereczek-Fossa BA et al (2021) Intraoperative irradiation for early breast cancer (ELIOT): long-term recurrence and survival outcomes from a single-centre, randomised, phase 3 equivalence trial. Lancet Oncol 22(5):597–608. https://doi.org/10.1016/S1470-2045(21)00080-2
doi: 10.1016/S1470-2045(21)00080-2
pubmed: 33845035
Orrantia-Borunda E, Anchondo-Nuñez P, Acuña-Aguilar LE et al (2022) Subtypes of breast cancer. In: Mayrovitz HN (ed) Breast cancer [internet]. Exon Publications, Brisbane. https://www.ncbi.nlm.nih.gov/books/NBK583808/ . doi: https://doi.org/10.36255/exon-publications-breast-cancer-subtypes
Pedersen RN, Esen BÖ, Mellemkjær L, Christiansen P, Ejlertsen B, Lash TL, Nørgaard M, Cronin-Fenton D (2022) The incidence of breast cancer recurrence 10–32 years after primary diagnosis. J Natl Cancer Inst 114(3):391–399. https://doi.org/10.1093/jnci/djab202
doi: 10.1093/jnci/djab202
pubmed: 34747484
Polgár C, Major T, Fodor J, Németh G, Orosz Z, Sulyok Z, Udvarhelyi N, Somogyi A, Takácsi-Nagy Z, Lövey K, Agoston P, Kásler M (2004) High-dose-rate brachytherapy alone versus whole breast radiotherapy with or without tumor bed boost after breast-conserving surgery: seven-year results of a comparative study. Int J Radiat Oncol Biol Phys 60(4):1173–1181. https://doi.org/10.1016/j.ijrobp.2004.05.012
doi: 10.1016/j.ijrobp.2004.05.012
pubmed: 15519789
Polgár C, Fodor J, Major T, Sulyok Z, Kásler M (2013) Breast-conserving therapy with partial or whole breast irradiation: ten-year results of the Budapest randomized trial. Radiother Oncol 108(2):197–202. https://doi.org/10.1016/j.radonc.2013.05.008
doi: 10.1016/j.radonc.2013.05.008
pubmed: 23742961
Polgár C, Ott OJ, Hildebrandt G, Kauer-Dorner D, Knauerhase H, Major T, Lyczek J et al (2017) Late side-effects and cosmetic results of accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: 5-year results of a randomised, controlled, phase 3 trial. Lancet Oncol 18(2):259–268. https://doi.org/10.1016/S1470-2045(17)30011-6
doi: 10.1016/S1470-2045(17)30011-6
pubmed: 28094198
Russo AL, Taghian AG (2013) Fat necrosis of the breast in the accelerated partial breast irradiation era: the need for a universal grading system. Breast Cancer Res Treat 140(1):1–11. https://doi.org/10.1007/s10549-013-2611-1
doi: 10.1007/s10549-013-2611-1
pubmed: 23797180
Shah C, Badiyan S, Ben Wilkinson J, Vicini F, Beitsch P, Keisch M, Arthur D, Lyden M (2013) Treatment efficacy with accelerated partial breast irradiation (APBI): final analysis of the American society of breast surgeons MammoSite
doi: 10.1245/s10434-013-3158-4
pubmed: 23975302
Smith BD, Bellon JR, Blitzblau R, Freedman G, Haffty B, Hahn C, Halberg F, Hoffman K, Horst K et al (2018) Radiation therapy for the whole breast: executive summary of an American society for radiation oncology (ASTRO) evidence-based guideline. Pract Radiat Oncol 8(3):145–152. https://doi.org/10.1016/j.prro.2018.01.012
doi: 10.1016/j.prro.2018.01.012
pubmed: 29545124
START Trialists’ Group, Bentzen SM, Agrawal RK, Aird EG, Barrett JM, Barrett-Lee PJ, Bentzen SM et al (2008) The UK standardisation of breast radiotherapy (START) trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet 371(9618):1098–107. https://doi.org/10.1016/S0140-6736(08)60348-7
doi: 10.1016/S0140-6736(08)60348-7
Strnad V, Ott OJ, Hildebrandt G, Kauer-Dorner D, Knauerhase H, Major T, Lyczek J et al (2016) 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Lancet 387(10015):229–238. https://doi.org/10.1016/S0140-6736(15)00471-7
doi: 10.1016/S0140-6736(15)00471-7
pubmed: 26494415
Strnad V, Krug D, Sedlmayer F, Piroth MD, Budach W, Baumann R, Feyer P, Duma MN, Haase W, Harms W, Hehr T, Fietkau R, Dunst J, Sauer R (2020) Breast cancer expert panel of the German society of radiation oncology (DEGRO). DEGRO practical guideline for partial-breast irradiation. Strahlenther Onkol. 196(9):749–763. https://doi.org/10.1007/s00066-020-01613-z
doi: 10.1007/s00066-020-01613-z
pubmed: 32350554
pmcid: 7449998
Vaidya JS, Wenz F, Bulsara M, Tobias JS, Joseph DJ, Keshtgar M, Flyger HL, Massarut S et al (2014) Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial. Lancet 383(9917):603–613. https://doi.org/10.1016/S0140-6736(13)61950-9
doi: 10.1016/S0140-6736(13)61950-9
pubmed: 24224997
Vaidya JS, Bulsara M, Baum M, Wenz F, Massarut S, Pigorsch S, Alvarado M, Douek M, Saunders C et al (2020) Long term survival and local control outcomes from single dose targeted intraoperative radiotherapy during lumpectomy (TARGIT-IORT) for early breast cancer: TARGIT-A randomised clinical trial. BMJ. 370:m2836. https://doi.org/10.1136/bmj.m2836
doi: 10.1136/bmj.m2836
pubmed: 32816842
pmcid: 7500441
Veronesi U, Cascinelli N, Mariani L, Greco M, Saccozzi R, Luini A, Aguilar M, Marubini E (2002) Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med 347(16):1227–1232. https://doi.org/10.1056/NEJMoa020989
doi: 10.1056/NEJMoa020989
pubmed: 12393819
Veronesi U, Orecchia R, Maisonneuve P, Viale G, Rotmensz N, Sangalli C, Luini A, Veronesi P, Galimberti V et al (2013) Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomised controlled equivalence trial. Lancet Oncol 14(13):1269–1277. https://doi.org/10.1016/S1470-2045(13)70497-2
doi: 10.1016/S1470-2045(13)70497-2
pubmed: 24225155
Vicini FA, Cecchini RS, White JR, Arthur DW, Julian TB, Rabinovitch RA, Kuske RR, Ganz PA et al (2019) Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial. Lancet 394(10215):2155–2164. https://doi.org/10.1016/S0140-6736(19)32514-0
doi: 10.1016/S0140-6736(19)32514-0
pubmed: 31813636
pmcid: 7199428
Vinante L, Avanzo M, Furlan C, Fiorica F, Perin T, Militello L et al (2019) Ten daily fractions for partial breast irradiation. Long-term results of a prospective phase II trial. Breast J 25(2):243–249. https://doi.org/10.1111/tbj.13195
doi: 10.1111/tbj.13195
pubmed: 30714257
Wazer DE, Lowther D, Boyle T, Ulin K, Neuschatz A, Ruthazer R, DiPetrillo TA (2001) Clinically evident fat necrosis in women treated with high-dose-rate brachytherapy alone for early-stage breast cancer. Int J Radiat Oncol Biol Phys 50(1):107–111. https://doi.org/10.1016/s0360-3016(00)01541-8
doi: 10.1016/s0360-3016(00)01541-8
pubmed: 11316552
Whelan TJ, Pignol JP, Levine MN, Julian JA, MacKenzie R, Parpia S, Shelley W, Grimard L, Bowen J, Lukka H, Perera F, Fyles A, Schneider K, Gulavita S, Freeman C (2010) Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med 362(6):513–520. https://doi.org/10.1056/NEJMoa0906260
doi: 10.1056/NEJMoa0906260
pubmed: 20147717
Whelan TJ, Julian JA, Berrang TS, Kim DH, Germain I, Nichol AM, Akra M, Lavertu S, Germain F et al (2019) External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID): a randomised controlled trial. Lancet 394(10215):2165–2172. https://doi.org/10.1016/S0140-6736(19)32515-2
doi: 10.1016/S0140-6736(19)32515-2
pubmed: 31813635
White JR, Winter K, Cecchini RS, Vicini FA, Arthur DW, Kuske RR et al (2019) Cosmetic outcome from post lumpectomy whole breast irradiation (WBI) versus partial breast irradiation (PBI) on the NRG Oncology/NSABP B39-RTOG 0413 phase III clinical trial. IJROBP. https://doi.org/10.1016/j.ijrobp.2019.06.384
doi: 10.1016/j.ijrobp.2019.06.384